论文部分内容阅读
采用重组干扰素α联合拉米夫定治疗慢性乙型肝炎（下简称慢乙肝）患者３１例（Ａ组），并与３１例仅行保肝和对症治疗的慢乙肝患者（Ｂ组）进行疗效比较。结果显示，两组临床、生化指标均获改善；Ａ组ＨＢｅＡｇ阴转率为６５．５％，Ｂ组仅１０．７％，两组比较差异显著（Ｐ＜０．０１）；Ａ组ＨＢＶ－ＤＮＡ均转阴，而Ｂ组无１例阴转。认为干扰素α联合拉米夫定治疗慢乙肝可改善患者的肝功、稳定病情，提高ｅ抗原阴转率。
31 patients with chronic hepatitis B (group A) treated with recombinant interferon α combined with lamivudine were treated with 31 patients with chronic hepatitis B (group B) who were given only hepatoprotective and symptomatic treatment Compare The results showed that the clinical and biochemical indexes were improved in both groups. The negative conversion rate of HBeAg in group A was 65.5% and that in group B was only 10.7% (P <0.01) DNA were negative, but no negative in group B. That interferon α combined with lamivudine treatment of chronic hepatitis B patients can improve liver function, stable condition, improve e antigen negative conversion rate.